Effects of the CRF1 receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups

Neuropharmacology

Volumn 39, Issue 8, 2000, Pages 1357-1367

  Kehne, John H ^a   Coverdale, Shane ^a   McCloskey, Timothy C ^a   Hoffman, Diane C ^a   Cassella, James V ^a  

^a NEUROGEN CORPORATION   (United States)

Author keywords

Anxiety; Corticotropin releasing factor; CP 154,526; CRF1 receptor antagonist; Separation induced vocalizations; Stress

Indexed keywords

ANXIOLYTIC AGENT; BUSPIRONE; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CLOZAPINE; DESIPRAMINE; DIAZEPAM; HALOPERIDOL; ZIMELDINE;

ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; MALE; MOTOR PERFORMANCE; NONHUMAN; PRIORITY JOURNAL; RAT; SEPARATION ANXIETY; VOCALIZATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY; BEHAVIOR, ANIMAL; BUSPIRONE; CLOZAPINE; DESIPRAMINE; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALOPERIDOL; INJECTIONS, INTRAPERITONEAL; MALE; PYRIMIDINES; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SOCIAL ISOLATION; STRESS, PSYCHOLOGICAL; VOCALIZATION, ANIMAL; ZIMELDINE;

EID: 0034112887     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(00)00043-5     Document Type: Article

References (59)

1. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 18:1998;63-101.
2. Arborelius L., Owens M.J., Plotsky P.M., Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. Journal of Endocrinology. 160:1999;1-12.
3. Bakish D. The patient with comorbid depression and anxiety: The unmet need. Journal of Clinical Psychiatry. 60:1999;20-24.
4. 1A receptors are not involved in clozapine's lack of cataleptogenic potential. Neuropharmacology. 35:1996;1645-1646.
5. 1 receptor antagonist on shock-elicited startle, a novel model for assessing antistress activity of compounds. Society of Neuroscience Abstracts. 24:1998;201.
6. Connor K.M., Davidson J.R.T. The role of serotonin in posttraumatic stress disorder: Neurobiology and pharmacotherapy. CNS Spectrums. 3(Suppl. 2):1998;43-51.
7. 1 receptor antagonist in the separation-induced vocalization model of anxiety in rat pup. Society of Neuroscience Abstracts. 24:1998;202.
8. Davidson J.R., DuPont R.L., Hedges D., Haskins J.T. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. Journal of Clinical Psychiatry. 60:1999;528-535.
9. Davis M., Walker D.L., Lee Y. Roles of the amygdala and bed nucleus of the stria terminalis in fear and anxiety measured with the acoustic startle reflex. Annals of the New York Academy of Sciences. 821:1997;305-331.
10. De Vry J., Benz U., Schreiber R., Traber J. Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. European Journal of Pharmacology. 249:1993;331-339.
11. Dieterich K.D., Lehnert H., De Souza E.B. Corticotropin-releasing factor receptors: An overview. Experimental and Clinical Endocrinology and Diabetes. 105:1997;65-82.
12. Dow B., Kline N. Antidepressant treatment of posttraumatic stress disorder and major depression in veterans. Annals of Clinical Psychiatry. 9:1997;1-5.
13. Gardner C.R. Distress vocalization in rat pups. A simple screening method for anxiolytic drugs. Journal of Pharmacology Methods. 14:1985;181-187.
14. Goodman W.K., Price L.H., Delgado P.L., Palumbo J., Krystal J.H., Nagy L.M., Rasmussen S.A., Heninger G.R., Charney D.S. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Archives of General Psychiatry. 47:1990;577-585.
15. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacology and Therapeutics. 82:1999;1-99.
16. Griebel G., Perrault G., Sanger D.J. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP 154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology (Berlin). 138:1998;55-66.
17. Hofer M.A. Multiple regulators of ultrasonic vocalizations in the infant rat. Psychoneuroendocrinology. 21:1996;203-217.
18. Imaki T., Vale W. Chlordiazepoxide attenuates stress-induced accumulation of corticotropin-releasing factor mRNA in the paraventricular nucleus. Brain Research. 623:1993;223-228.
19. Insel T.R., Winslow J.T. Rat pup ultrasonic vocalizations: An ethologically relevant behavior responsive to anxiolytics. Olivier B., Mos J., Slangen J.L. Animal Models in Psychopharmacology. 1991;15-36 Birkhauser Verlag, Basel.
20. Kalus O., Asnis G.M., Rubinson E., Kahn R., Harkavy-Friedman J.M., Iqbal N., Grosz D., van Praag H., Cahn W. Desipramine treatment in panic disorder. Journal of Affective Disorders. 21:1991;239-244.
21. Kehne J.H., Baron B.M., Harrison B.L., McCloskey T.C., Palfreyman M.G., Poirot M., Salituro F.G., Siegel B.W., Slone A.L., Van Giersbergen P.L.M., White H.S. MDL 100,458 and MDL 102,288: two potent and selective glycine receptor antagonists with different functional profiles. European Journal of Pharmacology. 284:1995;109-118.
22. th Meeting Scientific Abstracts, p. 212.
23. Kehne J.H., McCloskey T.C., Baron B.M., Chi E.M., Harrison B.L., Whitten J.P., Palfreyman M.G. NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations. European Journal of Pharmacology. 193:1991;283-292.
24. Kehoe P., Harris J.C. Ontogeny of noradrenergic effects on ultrasonic vocalizations in rat pups. Behavioral Neuroscience. 103:1989;1099-1107.
25. 2C receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety. Psychopharmacology (Berlin). 114:1994;90-96.
26. Klint T., Andersson G. Ultrasound vocalization is not related to corticosterone response in isolated rat pups. Pharmacology, Biochemistry and Behavior. 47:1994;947-950.
27. Koob G.F., Heinrichs S.C., Pich E.M., Menzaghi F., Baldwin H., Miczek K., Britton K.T. The role of corticotropin-releasing factor in behavioral responses to stress. Chadwick D.J., Marsh J., Ackrill K. Corticotropin-Releasing Factor, Ciba Foundation Symposium. 172:1993;277-289.
28. Kravitz H.M., Logg L., Fawcett J., Edwards J. Antidepressnt or antianxiety? A study of the efficacy of antidepressant medication. Psychiatry Research. 32:1990;141-149.
29. Ladd C.O., Owens M.J., Nemeroff C.B. Persistent changes in corticotropin-releasing factor neuronal systems induced by maternal deprivation. Endocrinology. 137:1996;1212-1218.
30. Londborg P.D., Woklow R., Smith W.T., DuBoff E., England D., Ferguson J., Rosenthal M., Weise C. Sertraline in the treatment of panic disorder: a multisite, double-blind, placebo-controlled, fixed-dose investigation. British Journal of Psychiatry. 173:1998;54-60.
31. Lundkvist J., Chai Z., Teheranian R., Hasanvan H., Bartfai T., Jenck F., Widmer U., Moreau J-L. A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. European Journal of Pharmacology. 309:1996;195-200.
32. Lydiard R.B., Morton A., Emmanuel N.P., Zealberg J.J., Laraia M.T., Stuart G.W., O'Neill P.M., Ballenger J.C. Preliminary report: Placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacology Bulletin. 29:1993;183-188.
33. 1 receptor antagonist. European Journal Pharmacology. 323:1997;21-26.
34. McDougle C.J., Goodman W.K., Price L.H. The pharmacotherapy of obsessive-compulsive disorder. Pharmacopsychiatry. 26(S1):1993;24-29.
35. Molewijk H.E., Hartog K., van der Poel A.M., Mos J., Olivier B. Reduction of guinea pig pup isolation calls by anxiolytic and antidepressant drugs. Psychopharmacology. 128:1996;31-38.
36. Molewijk H.E., van der Poel A.M., Mos J., van der Heyden J.A.M., Olivier B. Conditioned ultrasonic distress vocalizations in adult male rats as a behavioural paradigm for screening anti-panic drugs. Psychopharmacology. 117:1995;32-40.
37. Moore N.A., Tye N.C., Axton M.S., Risius F.C. The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. Journal of Pharmacology and Experimental Therapeutics. 262:1992;545-551.
38. Murphy D.L., Pigott P.A. A comparative examination of a role for serotonin in compulsive obsessive disorder, panic disorder and anxiety. Journal of Clinical Psychiatry. 51:1990;53-58.
39. Nowakowska E., Chodera A., Kus K. Anxiolytic and memory improving activity of fluoxetine. Polish Journal of Pharmacology. 48:1996;255-260.
40. Olivier B., Molewijk E., van Oorschot R., van der Heyden J., Ronken E., Mos J. Rat pup ultrasonic vocalization: effects of benzodiazepine receptor ligands. European Journal of Pharmacology. 358:1998;117-128.
41. Olivier B., Molewijk E., van der Heyden J., van Oorschot R., Ronken E., Mos J., Miczek K.A. Ultrasonic vocalizations in rat pups: effects of serotonergic ligands. Neuroscience and Biobehavior Review. 23:1998;215-227.
42. Reist C., Kauffmann C.D., Haier R.J., Sangdahl C., DeMet E.M., Chicz-DeMet A., Nelson J.N. A controlled trial of desipramine in 18 men with posttraumatic stress disorder. American Journal of Psychiatry. 146:1989;513-516.
43. Rex A., Voigt J.P., Voits M., Fink H. Pharmacological evaluation of a modified open-field test sensitive to anxiolytic drugs. Pharmacology, Biochemistry and Behavior. 59:1998;677-683.
44. Rocca P., Fonzo V., Scotta M., Zanalda E., Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatrica Scandinavica. 95:1997;444-450.
45. Sanchez C., Meier E. Behavioral profiles of SSRIs in animal models of depression, anxiety, and depression: Are they all alike? Psychopharmacology. 129:1997;197-205.
46. Sasson Y., Iancu I., Fux M., Taub M., Dannon P.N., Zohar J. A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. European Neuropsychopharmacology. 9:1999;191-196.
47. Schreiber R., Melon C., De Vry J. The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test. Psychopharmacology (Berlin). 135:1998;383-391.
48. Schulz D.W., Mansbach R.S., Sprouse J., Braselton J.P., Collins J., Corman M., Dunaiskis A., Faraci S., Schmidt A.W., Seeger T., Seymour P., Tingley III F.D., Winston W.N., Chen Y.L., Heym J.L. CP-154,526: A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proceedings of the National Academy of Sciences of the USA. 93:1996;10477-10482.
49. Skelton K.H., Owens M.J., Knight D.L., Ritchie J.C., Nemeroff C.B. The effects of chronic administration of the benzodiazepines, alprazolam and lorazepam, on hypothalamic and extra-hypothalamic CRF neuronal systems. Society of Neuroscience Abstracts. 24:1998;1489.
50. Skutella T., Probst J.C., Renner U., Holsboer F., Behl C. Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. Neuroscience. 85:1998;795-805.
51. Stein M.B., Liebowitz M.R., Lydiard R.B., Pitts C.D., Bushnell W., Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder). Journal of the American Medical Association. 280:1998;708-713.
52. Swiergiel A.H., Takahashi L.K., Kalin N.H. Attenuation of stress-induced behavior by antagonism of corticotropin-releasing factor receptors in the central amygdala in the rat. Brain Research. 623:1993;229-234.
53. Swiergiel A.H., Takahashi L.K., Rubin W.W., Kalin N.H. Antagonism of corticotropin-releasing factor receptors in the locus coeruleus attenuates shock-induced freezing in rats. Brain Research. 587:1992;263-268.
54. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M., Stalla G.K., Blanquet V., Steckler T., Holsboer F., Wurst W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor. Nature Genetics. 19:1998;162-166.
55. Tollefson G.D., Sanger T.M., Beasley C.M., Tran P.V. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biological Psychiatry. 43:1998;803-810.
56. Trosch R.M., Friedman J.H., Lannon M.C., Pahwa R., Smith D., Seeberger L.C., O'Brien C.F., LeWitt P.A., Koller W.C. Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Movement Disorders. 13:1998;377-388.
57. 1 receptor antagonist in the porsolt forced swim task. Society of Neuroscience Abstracts. 24:1998;201.
58. Wernicke J.F., Sayler M.E., Koke S.C., Pearson D.K., Tollefson G.D. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior. Depression and Anxiety. 6:1997;31-39.
59. Winslow J.T., Insel T.R. Serotonergic and catecholaminergic reuptake inhibitors have opposite effects on the ultrasonic isolation calls of rat pups. Neuropsychopharmacology. 3:1990;51-59.